Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.

NCT04118868 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Mycosis Fungoides

Interventions

COMBINATION_PRODUCT: Pembrolizumab administered using the Sofusa® DoseConnect™

Sponsor

Sorrento Therapeutics, Inc.